Murine models to evaluate novel and conventional therapeutic strategies for cancer - PubMed (original) (raw)
Review
Murine models to evaluate novel and conventional therapeutic strategies for cancer
James E Talmadge et al. Am J Pathol. 2007 Mar.
Abstract
Animal models, by definition, are an approximation of reality, and their use in developing anti-cancer drugs is controversial. Positive retrospective clinical correlations have been identified with several animal models, in addition to limitations and a need for improvement. Model inadequacies include experimental designs that do not incorporate biological concepts, drug pharmacology, or toxicity. Ascites models have been found to identify drugs active against rapidly dividing tumors; however, neither ascitic nor transplantable subcutaneous tumors are predictive of activity for solid tumors. In contrast, primary human tumor xenografts have identified responsive tumor histiotypes if relevant pharmacodynamic and toxicological parameters were considered. Murine toxicology studies are also fundamental because they identify safe starting doses for phase I protocols. We recommend that future studies incorporate orthotopic and spontaneous metastasis models (syngeneic and xenogenic) because they incorporate microenvironmental interactions, in addition to confirmatory autochthonous models and/or genetically engineered models, for molecular therapeutics. Collectively, murine models are critical in drug development, but require a rational and hierarchical approach beginning with toxicology and pharmacology studies, progressing to human primary tumors to identify therapeutic targets and models of metastatic disease from resected orthotopic, primary tumors to compare drugs using rigorous, clinically relevant outcome parameters.
Figures
Figure 1
A graphic overview of recommended steps in a screening and developmental strategy for novel therapeutics. This flow chart would be modified based on the characteristic of the therapeutic under development and would change for targeted molecular therapeutics, immunotherapeutics, and hormonal therapeutics.
Similar articles
- Models of metastasis in drug discovery.
Talmadge JE. Talmadge JE. Methods Mol Biol. 2010;602:215-33. doi: 10.1007/978-1-60761-058-8_13. Methods Mol Biol. 2010. PMID: 20012401 - Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
Newell DR, Burtles SS, Fox BW, Jodrell DI, Connors TA. Newell DR, et al. Br J Cancer. 1999 Nov;81(5):760-8. doi: 10.1038/sj.bjc.6690761. Br J Cancer. 1999. PMID: 10555743 Free PMC article. Clinical Trial. - What is the optimal rodent model for anti-tumor drug testing?
Kerbel RS. Kerbel RS. Cancer Metastasis Rev. 1998-1999;17(3):301-4. doi: 10.1023/a:1006152915959. Cancer Metastasis Rev. 1998. PMID: 10352884 Review. - The use of animal models in cancer drug discovery and development.
Curt GA. Curt GA. Stem Cells. 1994 Jan;12(1):23-9. doi: 10.1002/stem.5530120107. Stem Cells. 1994. PMID: 8142918
Cited by
- Delivery of mRNA with Histidine-Lysine Peptides.
Leng Q, He J, Anand A, Mixson AJ. Leng Q, et al. Methods Mol Biol. 2024;2822:367-386. doi: 10.1007/978-1-0716-3918-4_23. Methods Mol Biol. 2024. PMID: 38907929 - A murine model to evaluate immunotherapy effectiveness for human Fanconi anemia-mutated acute myeloid leukemia.
Huang T, Leung B, Huang Y, Price L, Gui J, Lau BW. Huang T, et al. PLoS One. 2024 Jan 30;19(1):e0292375. doi: 10.1371/journal.pone.0292375. eCollection 2024. PLoS One. 2024. PMID: 38289944 Free PMC article. - Mouse Melanoma Model in Tumor Vaccines and Immunotherapy Research.
De Robertis M, Lampreht Tratar U, Signori E, Komel T, Čemažar M. De Robertis M, et al. Methods Mol Biol. 2024;2773:157-163. doi: 10.1007/978-1-0716-3714-2_14. Methods Mol Biol. 2024. PMID: 38236544 - Azoxymethane/Dextran Sodium Sulfate (AOM/DSS) Model of Colorectal Cancer.
De Robertis M, Signori E. De Robertis M, et al. Methods Mol Biol. 2024;2773:51-58. doi: 10.1007/978-1-0716-3714-2_5. Methods Mol Biol. 2024. PMID: 38236535 - Evaluation of pain related behaviors and disease related outcomes in an immunocompetent mouse model of prostate cancer induced bone pain.
Jimenez-Andrade JM, Ramírez-Rosas MB, Hee Park S, Parker R, Eber MR, Cain R, Newland M, Hsu FC, Kittel CA, Martin TJ, Muñoz-Islas E, Shiozawa Y, Peters CM. Jimenez-Andrade JM, et al. J Bone Oncol. 2023 Oct 30;43:100510. doi: 10.1016/j.jbo.2023.100510. eCollection 2023 Dec. J Bone Oncol. 2023. PMID: 38075938 Free PMC article.
References
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130. - PubMed
- Talmadge JE, Wolman SR, Fidler IJ. Evidence for the clonal origin of spontaneous metastases. Science. 1982;217:361–363. - PubMed
- Talmadge JE, Fidler IJ. Cancer metastasis is selective or random depending on the parent tumour population. Nature. 1982;297:593–594. - PubMed
- Talmadge JE, Benedict K, Madsen J, Fidler IJ. Development of biological diversity and susceptibility to chemotherapy in murine cancer metastases. Cancer Res. 1984;44:3801–3805. - PubMed
- Schuh JC. Trials, tribulations, and trends in tumor modeling in mice. Toxicol Pathol. 2004;32(Suppl 1):53–66. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases